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Abstract
Cannabinoid pharmacology has been explored as a therapeutic option for handling
pathologies and conditions of  varying nature.  In regard to neurological  disorders,
cannabinoid chemistry has been explored for the regulation of hyperkinetic symptoms,
anti-inflammation, neuroprotection, and neurodegeneration, a collective goal of many
preclinical studies. The enhancement and improvement of the endogenous cannabiner‐
gic responses of the human body in both physiological and pathological conditions,
together with the overall consequential effects of the modulation of its elements, are
currently under strict scrutiny and undeniably possess incalculable value that might
support the hypothesis aiming to improve the endocannabinoid tone with therapeutic
purposes. Therefore, this chapter reviews the mechanisms known to be present in the
course of several disorders of the basal ganglia, as well as the available treatments exploring
this novel approach.
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1. Introduction
Cannabinoid signaling has been reported to play an active role in a number of neurological
diseases. Its functions begin with the constitutive expression of receptors within the central
nervous system (CNS), as well as inducible expression of such upon inflammatory processes;
in addition, endogenous ligands and the enzymes in charge of the synthesis and degrada‐
tion of endocannabinoids complete the arrangement. Therefore, the study of the cannabi‐
noid circuitry is currently directed towards the description of the events that typically take
place as part of the onset and development of disease, as well as the exploitation of the
experimental evidence that supports and enables novel and promising therapies. Given the
poor effectiveness of existing treatments in matter of neurological diseases, the interest of the
vast majority of such approaches involves strategies that aim to describe and explain com‐
mon alterations that occur at early stages of a number of disorders. Basal ganglia, compris‐
ing complex nuclei such as caudate, putamen, globus pallidus, or the substantia nigra, are
intimately associated with the endocannabinoid system (ECS) through the expression of its
receptors, inducement of synthesis of such compounds and, therefore, exert a prominent
modulatory motor function and some rewarding processes [1–4].
Such findings have greatly encouraged the study of the implications of cannabinoid-derived
compounds in neurological diseases from the basal ganglia. From motor-related striatal
disorders such as catalepsy or dystonias, to neurodegenerative diseases such as Alzheimer’s
disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), or even low-incidence
disorders such as glutaric or propionic acidemias, the efficacy of cannabinoids has and is still
being demonstrated in a number of pathological schemes, particularly through the reduc‐
tion of oxidative stress, neuroinflammation, and excitotoxicity, therefore enhancing intrinsic
restoration mechanisms [2, 5–7].
Nowadays, the progress towards effective therapeutic approaches involves mainly the
manipulation of the cannabinoid pathway through pharmacological means, with particular
emphasis in models capable of evoking neuronal cell death and impaired cell communica‐
tion; on the other hand, the exploration of cannabinoid compounds able to trigger endoge‐
nous responses has gained popularity given several hypotheses claiming promissory
neuroprotective qualities of endocannabinoids, despite the heterogeneous data that has been
retrieved so far. Nevertheless, the therapeutic use of cannabinoid compounds has raised and
will most surely continue to raise questions regarding its capacity in long-term outlines, as
well as the potential risks acquired when dealing with the design of therapies, all of which
need to be addressed accurately. The challenge remains, and contemporary therapeutic
advances must respond to these questions; therefore, this chapter will provide with punctu‐
al evidence of the known mechanisms that underlie the onset and development of the
aforementioned diseases of the basal ganglia and the available treatment regimes, and together
with a current overview of the mechanisms of action of endocannabinoids under physiologi‐
cal and pathological conditions, will contribute to paint a realistic picture of the area of
competence of cannabinoids in basal ganglia disease, and its perspectives in short and long
term.
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2. Neurological diseases and the potential cannabinoid therapies
2.1. Alzheimer’s disease
Since the first description of AD over a 100 years ago, our knowledge of the mechanisms
underlying this condition has evolved and enriched ever since. Consistent pathological traits
of AD include the presence of extracellular deposits of β-amyloid peptide which, through
several mechanisms, are thought to play a relevant role in the origins of the disease by inducing
cell death and consequent memory, behavioral and cognitive detriment. A second feature
encompasses the formation of intracellular neurofibrillary tangles of tau protein, which
eventually impairs neuronal communication [6, 8, 9]. In addition, such hallmarks are accom‐
panied by influential conditions that have attracted increasing interest by acquiring value as
causal agents of the disease. First, oxidative stress; as expected, an imbalance between pro-
oxidant and antioxidant systems leads to the accumulation of reactive oxygen species (ROS)
produced by the mitochondria, and, therefore, to unequivocal damage to lipids, proteins, and
nucleic acids. Second, a number of excitotoxicity events take place, especially when consider‐
ing that AD patients exhibit a considerable reduction in glutamate transporter activity, hence
easing neurodegeneration. In fact, several stressing stimuli (dysregulation of intracellular Ca2+
homeostasis, mitochondrial dysfunction, exposure to aberrant Aβ/tau proteins, oxidative
stress, and inflammation itself) are thought to run simultaneously and lead to AD progres‐
sion. While the vast majority of AD cases are idiopathic and with unknown etiology, a minority
have a genetic basis; the aforementioned conditions are involved thoroughly with its genesis
and evolution, and the disease is currently recognized as multifactorial.
From a different perspective, recent reports indicate that AD constitutes nowadays a note‐
worthy threat to the elder as it is a highly frequent condition among people over the age of 65
years (affecting up to 5–8% of individuals over 65 years, as high as 15–20% of individuals
over 75 years, or an alarming 25–50% of individuals over 85 years) [10]; also, it accounts as the
most prevalent disease among the dementias [11], accounting for 50–75% of the total num‐
ber of dementias [10]. As a consequence of the late onset of the disease, it occurs with other
major age-related pathologies, and therefore, an early and accurate diagnosis represents a great
challenge added to the consolidation of an effective therapy. As a result of such complexity,
substantial amount of efforts have been set towards the comprehension and treatment of this
condition.
Existing pharmacological therapies include cholinesterase inhibitors such as donepezil,
galantamine or rivastigmine [8], statins, and memantine. Unfortunately, all of those fail to
modify the course of the disease or reverse its progression. Moreover, current approved drugs
can only ameliorate symptoms in a limited number of patients facing initial features of the
disease; consequently, to improve the strategy, symptomatic therapies must be accurately
managed with patient’s comorbidities. Activated microglia at the periphery of senile pla‐
ques is known to contribute greatly with the antioxidant defense in brains of patients suffering
from the disease, and for that reason, anti-inflammation and antioxidant strategies are likely
to cast a feasible alternative for early stages of the disease. Also, research efforts have begun
to explore drug delivery vehicles and bioimaging at nanoscale, which despite comprising




revolutionary nanotech-based developments, still face impediments linked to its biological
toxicity, bioavailability, stability, and efficacy to name a few. Undoubtedly, the challenge into
the proposal and consolidation of an effective therapy still remains, and great emphasis has
been put into the study of therapeutic targets of AD and other neurodegenerative diseases.
2.2. Parkinson’s disease
PD is a neurodegenerative disorder characterized by several motor and non-motor signs
resulting from a progressive loss of dopaminergic neurons from the substantia nigra pars
compacta (SNpc) [12] and a selective degeneration of the nigrostriatal pathway [13]. Neuro‐
nal death occurs in other brain regions, such as locus coeruleus, the dorsal nucleus of the vagus
nerve, and the nucleus basalis of Meynert and might be even more acute than the neuronal
death from the SNpc [14]. However, the pathological processes of this disease involve far more
events than cell loss, primarily in routes in which non-dopaminergic neurotransmitters are
affected (and include noradrenalin, serotonin, glutamate, or acetylcholine in the basal ganglia
and cortex) [2]. PD accounts for the second most common neurodegenerative disorder among
the elder people worldwide, and hence, science has focused great amount of effort into its
comprehension. Along with the knowledge of the causes that lead to this illness, several
pathogenic mechanisms have been suggested; these include oxidative stress, mitochondrial
deficiency, proteolytic stress, and neuroinflammation [12, 15]. Also, it is now considered the
dopaminergic metabolism itself as another crucial factor in the cell death, taking into ac‐
count that it is the intracellular key source of ROS and that dopamine oxidation can generate
endogenous neurotoxins. To control the dopaminergic homeostasis, several enzymes such as
tyrosine hydroxylase (TH) or dopamine decarboxylase (DDC) play a very important role in
preventing the excessive oxidative stress; however, nigrostriatal levels of glutathione and
superoxide dismutase activity in PD’ patients are diminished, and therefore, cells are more
vulnerable to damage by oxidative stress. Together with ROS overload, some effects such as
lipid oxidation or electron transport chain decoupling take place, which are later translated
into cell death [2]. Taking into consideration that dopamine does not cross the blood–brain
barrier (BBB), drug therapy in this matter is palliative [16] and is mainly oriented to increase
dopamine levels through oral dopamine-replacement therapies. Such treatments include L-
dopa, dopamine agonist receptors, monoaminooxidase B inhibitors, and catechol-o-methyl‐
transferase (COMT) inhibitors. From the previous examples, L-dopa remains in our day as the
most prescribed treatment, as well as the most functional therapy to lessen motor symptoms.
Unfortunately, the neurodegenerative nature of this disease implies the progression of
symptoms with time, and frequently motor fluctuations and dyskinesias go on and accentu‐
ate; this ends up by promoting alternate periods with decreased motion and abnormal
involuntary movements [12]. In addition, L-dopa loses effectiveness and causes dyskinesias
and conduct abnormalities in many patients [17]; on the other hand, some patients do not
tolerate adequately dopaminergic agonists and need to substantially reduce dosage [2], and
even patients receiving other dopaminergic therapies develop abnormal conducts such as
impulse-controlled disorders or dopamine deregulation syndrome; furthermore, some non-
motor symptoms such as hallucinations may even accentuate with dopaminergic treatment
[12]. The motor and non-motor abnormalities presented by the effect of these limitations reduce
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drastically the quality of life of the patients suffering from this disease and intensify the need
of an efficient treatment.
2.3. Huntington’s disease
HD is a neurodegenerative disorder which follows an autosomal dominant inheritance and
exhibits choreic movements and adverse psychiatric and cognitive signs. The disease holds
grounds on a gene coding for the protein huntingtin, in which an abnormality exhibits from
40 up to 125 trinucleotide repeats (from a 38-trinucleotide repetitions in normal conditions);
hence leading to a toxic protein. Significant cognitive and psychiatric detriment and abnor‐
mal involuntary movements occur as part of the distinctive features of the condition; the
aforementioned symptoms are explained by the degeneration and cell death at the level of
globus pallidus, cortex, or striatum, all of which are accented with the progress over time [18].
The neurodegenerative quality of this pathology is attributed partially to the toxicity of the
mutant Htt, condition characterized by abnormal folding, abnormal proteolysis, aggregation/
protein deposition, to name a few. Nonetheless, despite the progress achieved in the defini‐
tion of the pathogenic mechanism that encloses this disease, the clinical expression, the
evolution, or even its genesis cannot be merely explained through the mutation of the Htt
protein [19], since oxidative events, excitotoxicity, glial activation, and local inflammatory
events converge with the onset and progression of the disease [3].
HD is a rare, chronic, and neurodegenerative disorder in which clinical symptoms start
typically once past 40 years; nevertheless, slight symptoms may be present even for decades
before diagnosis is met [1]. Recent epidemiologic data on the matter reveals that HD has an
incidence of 1–100 cases per million in Europe and North America only, while Japan, Hong
Kong or Taiwan has only up to 7 cases per million. In accordance with the stated figures, high-
incidence regions or “hot spots” have been identified, and correspond to each of the follow‐
ing: British Columbia and Canada, the city of Maracaibo in Venezuela, and South Wales region
in the United Kingdom [20]. Despite this scenario, current therapeutics lack of an effective
option to stop the progression of the disease; as a consequence, available treatments consist
mainly of antipsychotics, antidepressants, and sedatives, as well as psychological treatment
and rehabilitation [20–27]. For these reasons, notorious efforts to elucidate the pathophysio‐
logical mechanisms that underlie this condition were executed intensely during the last
decade.
2.4. Multiple sclerosis
Multiple sclerosis (MS) is a demyelinating disorder of the CNS that is characterized by a
number of progressive and disabling symptoms of inflammatory and degenerative nature;
affecting up to 2.5 million people worldwide, MS accounts as one of the most common cause
of neurological disability in young adults (from 20 to 40 years). MS has accompanied human
beings for about 150 years, time in which the disorder has been target of enormous endeav‐
ors that have aimed to describe and understand the underlying mechanisms. In regard to the
causes that lead to this illness, strong evidence indicates that a particular genotype plus
environmental or somewhat random stimulus may led individuals more prone to develop the




disorder [5, 28, 29]. MS patients experience immune attack to the CNS, exerting acute damage
to the glial cells that form myelin, the oligodendrocytes. In addition, the autoimmune acute
inflammation can be spotted along brain matter and meninges. In this form, loss of neurons is
eventually reached as the demyelination process turns chronic and is convoyed by severe
degeneration of axons; as expected, neuronal loss is linked with the disability manifested
throughout the disease, a condition that lessens dramatically the quality of life of patients. MS
can portray neuronal dysfunction, and states of accumulated or irreversible disability, and
even some cases exhibit both [30].
Central manifestations of the disease involve “relapses,” or exacerbation periods, which are
often followed by “remissions,” which are partial or complete recovery periods. Primary-
progressive MS, PPMS, is considered the only phase of this condition and estimated to affect
around 10% of the people with MS. A high percentage of MS patients are likely to be initial‐
ly diagnosed with a relapsing–remitting disease course, or RRMS, a stage that will most surely
shift to the so-called secondary-progressive MS, or SPMS. Unfortunately, the neurodegener‐
ative nature of the disease implies that after a period of relapses and remissions, MS’ steady
progression will be reached either with or without relapses. Consequently, the distressing
outcome that characterizes MS has drawn the attention of the medical fields in order to improve
the quality of life of patients who endure it through valid therapeutic options; unfortunately,
the etiology remains unknown, and to this date, there is no definite treatment. Moreover,
despite a myriad of efforts and even after a century of awareness and constant research, MS
therapeutics still face major challenges as a proper diagnose is hard to meet given the lack of
a leading and straightforward test that prevents from missed and incorrect diagnoses.
Thus, while we face the lack of a cure or effective treatment, research has offered several
disease-modifying drugs (DMDs), which help reducing MS activity and improve the overall
course of the disease. Approved treatments for MS are diverse and include glatiramer acetate,
immunomodulatory compound approved by the FDA for the reduction of the frequency of
relapses of MS and, however, does not reduce progression of disability; on the other hand,
mitoxantrone is an antineoplastic agent that has shown effectiveness in slowing the progres‐
sion of secondary-progressive MS, a stage of the disease that follows the relapsing–remitting
disease course; although this therapy provides some benefit, the use of agents of this nature
carries several adverse reaction of varying severity, which limits usage in MS patients; lastly
fingolimod, a selective immunosuppressive drug currently approved in the United States as
a first-line treatment, or otherwise approved in countries of the European Union as a second-
line treatment given safety clauses [30]. The previously stated therapies are effective to some
extent and mainly regulate the immune system activity but have no competence to repair
immune-mediated damage to the myelin sheaths, turning them worthless for neurodegener‐
ative scenarios. Alternatively, with remyelination therapies, neuronal function can be restored,
and some future neuronal loss can be prevented. A therapy of this class is substantiated with
the proposal that a treatment that enhances remyelination might be even more effective in
reducing long-term disability due to the increase in neuronal survival. For these purposes,
monoclonal antibodies such as alemtuzumab and BIIB033 are few examples of novel at‐
tempts on the mater, and so far, the promotion of remyelination has proven to reduce overall
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clinical severity in animal models of the disease [31]. Despite moving towards clinical studies,
several factors have been found to contribute to failure of the approach, as sporadically
oligodendrocytes do not remyelinate axons effectively; moreover, oligodendrocyte precur‐
sor cells (OPC) are not always recruited into the lesions at functional levels [28, 31].
2.5. Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a motor neuron disorder with a fatal outcome, and
accounts as one of the most devastating disorders in adults, as approximately 70% of pa‐
tients die within 3 years from the beginning of symptoms. Often referred to as “Lou Gehrig’s
disease,” ALS brain exhibits severe damage on motor neurons in brain, brainstem, and spinal
cord; the disease is clinically characterized by a high-degree of cognitive impairment, as well
as progressive motor manifestations such as muscular atrophy and consequential respirato‐
ry complications and paralysis, all of which constitute possible and unfortunate death causes
for those who suffer from it. With an indefinite pathogenesis, ALS is known to comprise
environmental and genetic factors. In this form, the highest percentage of ALS cases are
sporadic, while only 10% are familial with dominant inheritance. Aberrant folding of Cu/Zn
superoxide dismutase (SOD1) is a pathological change known to be present in the familial
form of ALS (fALS) caused by several mutations in the SOD1 gene; such alterations are still
under scrutiny and current hypotheses state that such result in protein misfolding and
fibrillary aggregation observed as part of the hallmarks of ALS. As expected, the assessment
of the environmental factors that may be associated to the disease is imperative; however,
many more studies from different sources are needed to judge appropriately such relation‐
ship and determine accurately the risk factors that come along with it. Early diagnosis of ALS
is based mainly on the neurologist judgment of clinical signs and symptoms and constitutes a
crucial element to ensure quality of life; nevertheless, diagnosis is often met a year, or up to 3
years, before the first symptoms, creating an obstacle to adequate medical care. Besides, very
few therapeutic alternatives are currently licensed as treatment for the ALS; a great example
is riluzole, a potent inhibitor of glutamate release used recurrently to delay the onset of
particular symptoms, but which does not result in substantial benefit in terms of therapeutic
effects. Still, emerging evidence indicates that numerous factors may contribute strongly with
the degenerative process of the disorder; primarily, the influence of enhanced oxidative stress
and neuroinflammation events, which is also hypothesized as causative agents for other high-
incidence diseases such as AD or PD; additionally, glutamate toxicity, mitochondrial dysfunc‐
tion, or excessive apoptosis contribute actively to the progression of the disease and entail the
basis of proposed therapies to delay neural loss and prolong cell survival [32–36].
Likewise, numerous evidence is implicating the receptor for advanced glycation end-prod‐
ucts, or RAGE, as part of the genesis of several disorders. RAGE is known to be part of cell
surface immunoglobulins, and its role as a factor of oxidative stress, inflammation, and cellular
detriment in neurodegenerative diseases is gaining attention over the years. The precise
mechanisms underlying the involvement of RAGE in neurodegeneration and its detrimental
effects remain unknown, and yet some studies have provided valuable suggestions of RAGE
as a crucial contributor of the pathogenesis of ALS; of special interest are those works that




demonstrate the upregulation of AGE receptors and its ligands, revealing an interesting trace
to further look into on experimental approaches [33]. In this form, many more hypotheses and
experiments are needed to reach definite understanding of the etiopathogenesis of ALS.
2.6. Organic acidemias
Organic acid disorders are autosomal-recessive inherited metabolic disorders that appear as
a result of an aberrant step in the catabolic route of branched-chain amino acids, usually the
consequence of deficient enzyme activity. In this form, organic acids tend to accumulate in
fluids and tissues, followed by various pathological effects such as overdosage of toxic
chemical compounds, as well as shortage of essential compounds omitted with the interrup‐
tion of inner pathways. Examples of disorders under the latter classification include propion‐
ic acidemia, methylmalonic acidemia (MMA), homocystinuria, 3-hydroxy-3-methylglutaryl-
CoA (HMG-CoA) lyase deficiency, and type I glutaric acidemia (GA I). A recurrent clinical
manifestation of such disorders comprises encephalopathy, which consist of neurologic
symptoms as seizures, lethargy, and malnutrition, all of which progress over time and lead to
coma. Therefore, the term “organic acidemia” (OAs) has been applied to a group of disor‐
ders characterized by the excretion of nonamino organic acids in urine and accounts as the
most frequent metabolic disorders among severely ill children. In this way, those who endure
it often present acute symptoms early in life; prompt diagnosis is thus a crucial element to
avoid irreversible brain damage, as lack, tardy, or incorrect treatment would lead to low quality
of life and permanent neurological consequences. Likewise, several organizations working
towards the awareness and understanding of metabolic diseases have emphasized the
importance of prenatal diagnosis for cases with elevated risk factors through the analysis of
amniotic fluid, enzyme activity, or DNA testing. Such efforts have thrown some sampling and
tests that have been useful for this purpose, such as very long chain fatty acids or lysosomal
enzymes; however, the elevated costs along with the lack of consciousness of the implied
consequences have slowed the progress in the matter.
The hereditary element of the disease signalizes the increased number of risk factors of
offspring presenting an OAs; in this form, as OAs are considered rare, adequate assessment
of the prevalence of the disease would need to rely on rigorous and periodic reports; howev‐
er, the reportage of its presence among the population is irregular. Thereby, high prevalence
has been theorized in Porto Alegre, Brazil, and South Indian regions, as well as some Western
countries; in addition, several cases have been followed closely at health institutions from
Damascus, Syria. Luckily, the elevated presence of these disorders over the past 20 years
increased noticeably the efforts towards its study. So that the diagnostic elements and clinical
features of these disorders of metabolic nature are increasingly being documented. Consider‐
ing the poor prognosis faced by patients, lots of efforts have been placed into the treatment of
the manifestations of these disorders. Options imply the restoration of the biochemical
homeostasis in regard to the specific aberrant element, usually through complete treatment
schedules of dietary restriction of the precursor amino acids, administration of adjunctive
compounds to dispose the toxic metabolites, or enhancement of the deficient enzymes.
Additionally, patients often require liver transplantation given the high demand on this organ;
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however, only a minority has access to such alternatives, and even less patients find success
with this alternative [37–40].
In spite of its concrete aberrations, search of new clinical options has reached this neurometa‐
bolic disorders. Along with the accumulation of several metabolites, including glutaric,
methylmalonic, and propionic acid, a severe neurodegenerative process takes place in OAs
brain of children; the latter, as known, is associated with many other damage mechanisms
from oxidative stress to excitotoxicity. In this form, the benefits and multiple advantages or
proposed neuroprotective therapies could provide invaluable input for such disorders.
3. The role of the cannabinoid system in neurodegenerative diseases
The ECS has been formally recognized as such for around 20 years, and its study has yield‐
ed information that reveals the close relationship of this system in the brain. As known, type
1 cannabinoid receptors (CB1r) are widely expressed within the CNS, in particular in the motor
cortex, thalamus, hypothalamus, and hippocampus to name a few. On the other hand, type 2
cannabinoid receptors (CB2r) are found in the CNS as well as peripheral tissue. Cannabi‐
noid circuitry is associated with a number of physiological processes, as endogenous canna‐
binoids such as 2-arachidonoyl glycerol (2-AG) or anandamide (AEA) interact with the G-
protein-coupled receptors, CB1r and CB2r, and are known to regulate the neurotransmitter-
release inhibition through the adenylate cyclase inhibition [41].
Given the foregoing in regard to the current status of AD and its therapeutics, the high density
of CB1r in the basal ganglia tipped the balance towards a scenario in which particularly this
receptor could provide evidence that highlight the therapeutic potential of the ECS in the AD.
Moreover, subpopulations of the CB1r located at the hippocampus are well-known to
contribute to the effect in memory and learning, processes that face great detriment during the
progression of AD and are also features of the AD brain [42]. It is strongly suggested that
cannabinoids hold anti-inflammatory and antioxidant properties that result in an overall
neuroprotective effect; this is hypothesized to occur through the promotion of several intrinsic
repair mechanisms able to reduce oxidative stress or apoptotic events. A number of studies
have supported the fact that neuronal survival is intimately related with cannabinoid circuitry,
hence diminishing the deleterious effect of harmful molecules such as Aβ in AD. Neuronal
damage is known to trigger the endogenous production of cannabinoids such as AEA [43].
Also, Aβ is known to evoke hippocampal degeneration and cognitive impairment, but would
also be responsible of inducing an increase in the production of 2-AG; as a consequence, ECS
would exert its neuroprotective actions from Aβ-induced dent [44]. On the other hand, the
overactivation of the N-methyl-D-aspartate receptor (NMDAr) and dysregulation of intracel‐
lular Ca2+ homeostasis portray the unique hallmarks of the disease and ultimately hold great
potential for novel therapeutic strategies. Such an outline implies the manipulation of the ECS
to promote a response which ideally involve the upregulation in the endocannabinoid
synthesis, or the reduction of the Ca2+ influx and the consequent suppression in the excitotox‐
ic events to confer neuroprotection. Conveying those coveted effects, evidence suggests that




the activation of the CB1r is capable of exerting protective actions in cells in the hippocam‐
pal region, action that would be completed through the inhibition of Ca2+ entry and reduc‐
tion of the glutamatergic activity [45]; in this matter, several experiments with inhibitors of the
NMDAr have shown to protect cell cultures from excitotoxic damage; in addition, it is now
known that the synthesis of the two main cannabinoids of endogenous nature, AEA and 2-
AG, is dependent of Ca2+ influx, and thus, levels of compounds of cannabinoid basis would be
determined in response to the intracellular Ca2+ load. On the other hand, CB2r is also of interest,
and so far, its anti-inflammatory properties and neurogenesis stimulation have been proven
as well. In conclusion, the promissory potential of the ECS satisfies the demands of a neuro‐
degenerative condition with no cure or adequate treatment to this date. The abovemen‐
tioned strategies represent interesting actions of the cannabinoids; until now, the manipulation
of the ECS has yielded promising results and might be more efficient than the present choices.
Cannabinoids have shown to reduce oxidative stress and neuroinflammation markers,
typically Aβ-related, while fundamental restoration mechanisms are increased [8]. In this way,
the AD therapeutics strongly call for further research to demonstrate conclusively such
properties, in order to respond accordingly to the needs of those who endure it.
On the other hand, current pharmacological therapy in PD relies on formulations unable to
attain suitable efficiency; in response to this condition, the potential of cannabinoid com‐
pounds has attracted attention to the field, as well as the possible applications with count‐
less clinic value. As known, cannabinoid receptors are currently being associated to a number
of neuropathogenic processes as various reports affirm that such molecules may act as ideal
means for pathologies with inflammatory components. In regard to these events, the devel‐
opment of dyskinesias constitutes a disabling complication shown by most PD’ patients; for
that reason, CB1r antagonists are proposed as an accurate treatment for parkinsonian
symptoms (bradykinesia, rigidity, tremor, and so on) as well as levodopa-induced dyskine‐
sias through the inhibition of such abnormal movements [46]. Furthermore, increasing
evidence has disclosed that ECS goes through a number of alterations during brain disor‐
ders and PD is not an exception. To this point, it is known that dopamine depletion imposes
great impact into the ECS and causes an upregulation of the CB1r and endocannabinoids in
basal ganglia, which of course fundaments the multiple hypothesis regarding cannabinoid
applications. In fact, published data states that an early pre-symptomatic phase in PD would
display desensitization or downregulation of CB1r, and which ultimately lead to excitotoxic‐
ity, oxidative stress, and inflammatory events; on the other hand, advanced phases of the
disease would exhibit upregulation of CB1r consistently with the hyperkinesia manifested by
patients [18]; in this form, the opportunity area in the different stages is evident. In regard to
the experimental revisions, several studies report that the use of rimonabant, another
antagonist of the CB1r, could trigger positive effects on parkinsonian motor inhibition; the
results, however, seem to be related to low-dose schemes [47]. Then again, the prompt
administration of inhibitors of the degradation of endogenous cannabinoids may be able to
reduce typical motor symptoms of the disease, as it has been found that cerebrospinal fluid
contains high levels of endogenous cannabinoids such as AEA [48] in patients’ treatment-
naïve; this constitutes a remarkable finding, and such an approach represents a feasible
challenge for clinicians. In this way, research on the matter has disclosed so far that both
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agonists and antagonists of cannabinoid receptors are likely to improve some but not all motor
symptoms, and further clinical trials might provide additional information needed to
appropriately identify such compounds and migrate from research to clinic. However, some
studies have not found noteworthy effects of cannabinoids in PD; a remarkable example is the
orally administered cannabis, as it did not produce either qualitative or quantitative improve‐
ment in dyskinesias or parkinsonism [48]. Over the same goal, innovative experimental
designs determined that the administration of Δ9-tetrahydrocannabinol (Δ9-THC) or cannabi‐
diol, both full agonists of CB1r, lead to significant protection of dopaminergic neurons of the
nigrostriatal pathway after great toxic insult with 6-hydroxydopamine (6-OHDA). Likewise,
Δ9-THC and cannabidiol weakened the dopaminergic depletion resulting from a toxic insult
with 6-OHDA toxin and lessened the tyrosine hydroxylase deficits [21]. Then again, the
dramatic loss of neurons in substantia nigra and striatum that distinguishes PD from the rest
entails consequences besides the alterations in the dopaminergic transmission. Glutamater‐
gic excitation is known to be mediated strongly by NMDAr with located at such brain regions,
and as known, overactivation of NMDAr leads to excitotoxicity events and great cellular
damage. In this form, antagonists of NMDAr of cannabinoid nature such as rimonabant hold
viable qualities for the treatment applications by reducing its elevated activity and reducing
drastically inflammatory events. Although exciting and promising, these new approaches
revealed somewhat conflicting results as a positive outcome was not always reached; therefore,
the proposal of clinical strategies to accurately treat PD must be followed by supplementary
research that provides grounds for its migration towards the clinic.
Research has expanded to low-incidence diseases such as HD, and so far, it is known that initial
phases display a downregulation of CB1r, a stage mostly pre-symptomatic and usually pre-
diagnose [24]. As part of the degenerative process, advanced states of the disease exhibit an
important loss of the CB1r in the striatum, GP, and SNpc in particular, but which might spread
further [27, 49].
It is well known that cannabinoid signalling pathways face great alterations as part of the
ruling elements of the disease; to start with, CB1r show evidence of deregulation and hypo‐
function in basal ganglia. Such findings differed with the traditional paradigm in which the
receptor loss was attributed as a secondary effect of the progressive loss of GABAergic neurons;
however, recent evidence has revealed that such loss is present also in models without striatal
lesion. Hence, it has been established that decrease and functional loss of CB1r may perhaps
be related with the pathogenesis of HD and not a mere consequence in the line of events;
moreover, alterations and overall detriment in CB1r may actually contribute with the onset
and progression by rendering neurons more vulnerable to oxidative stress and excitotoxicity
[3].
A strong exploration of plentiful strategies under this understanding started a few years ago,
and so far, the power of cannabinoids as toxicity modulators has been challenged. It was
recently reported that tetrahydrocannabivarin (Δ9-THCV) delays disease progression and
reduces motor inhibition through changes in glutamatergic transmission [50]. Preclinical
models of the disease have been used as platforms to explore the scope and limitations of
cannabinoid derivatives in therapy. Administration of cannabigerol (CBG) was capable of




reducing reactive microgliosis and counteracted the overregulation of inflammatory mark‐
ers in preclinical models with neurotoxin administration, and all of which were explained
through a cannabinoid receptor-dependent mechanism [51]; likewise, R6/1 transgenic mice
expressing ≥115 CAG repetitions displayed lower toxicity markers after the administration of
synthetic cannabinoids such as WIN 55,212-2 or HU210 through a CB1r coupling mecha‐
nism [52].
While a number of alternatives continue to justify its benefits and disadvantages in the run for
the establishment as competent therapies, new hypotheses have raised in regard to the
involvement of the ECS in neurodegenerative diseases, and MS is not an exception. Unlike
cannabinoid applications on AD or HD in which data suggests a definite trend of positive
outcomes, MS deals with rather differing data in terms of the etiopathogenesis of the disease.
The immune attack that takes place in MS is reported to come along with the decrease in
endocannabinoid levels due to the alteration of receptors in purinergic signalling induced by
some cytokines, hence declining the endocannabinoid tone [10]; in this form, such altera‐
tions may contribute with both the onset and progression of the disease by reducing endo‐
cannabinoid protection. On the other hand, several reports state that immune attack comes
along with endocannabinoid increase in several models of the disease (encephalomyelitis, or
EAE), arrangement in which cannabinoids would serve, once again, as neuroprotectors [5].
Despite conflicting, strategies involving the ECS encompass a wide range of approaches; up
to this date, several studies currently evaluate the role of synthetic cannabinoids on the
improvement of symptoms. For example, spasticity was proven to be dependent on the
complete action of CB1r, but not CB2r in preclinic studies with CB1-knockout mice [53]. In fact,
the motor disability nature of MS is conferred partly by spasticity, reason why this symptom
has been target of novel hypothesis; while a great number of such still stand preclinical
evaluations, some have reached further stages. Several clinical trials have confirmed the results
obtained previously, given that beneficial effects on spasticity symptoms were reached when
patients received experimental therapies with dronabinol [54]. Sativex®, a mixture of Δ9-THC
and cannabidiol in 50% ethanol solution, is currently approved in countries such as Canada,
Germany, and the United Kingdom to alleviate spasticity in patients with MS that was
somewhat unresponsive to standard therapies [55, 56]. As far as this, the applications born
from the exploitation of cannabis derivatives and the overall study of the ECS are vast and
have yielded valuable insights that help clarify the events that take place in the MS brain, as
well as the future outlook in terms of treatment and care. However, supplementary data are
needed to ascertain innovative cannabinoid therapies, as well as to ensure efficacy and safety
of those already under study.
Accordingly, several preclinical studies involving animal models of ALS have evaluated the
efficacy of CB2r activation in terms of motor symptom reduction and overall cell survival. for
example, regular administration of the selective antagonist of CB2r AM-1241 was found to
significantly decrease degeneration of motor neurons in a transgenic mouse model of ALS;
more importantly, motor function was preserved under schemes of early administration after
the onset of symptoms [57]. Experimental approaches using a mouse model of ALS, the
SOD1*G93A, disclosed congruent results with the above statements, given that noteworthy
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delay on progression of the disease was reached under treatment with WIN 55,212-2. This
potent CB1r agonist is going under strict scrutiny as many analgesic and anti-neurotoxic effects
have been attributed to its chemical structure; thus, the exploitation of the vast properties of
this molecule is currently at its height and further research will surely follow. A genetic model
of the disease comprising the ablation of the FAAH was also tested, and revealed valuable
information in regard to the same animal model approach; as such, the consequential increase
of endogenous levels of AEA led to weakening of ALS symptoms and disease progression on
the SOD1 aged-animal model, results that, however, did not spread to the overall life-span
[36]. The previous are only few examples that emphasize the necessity of supplementary
studies that challenge the actual properties of cannabinoids and ECS management for
therapeutic means. Expressly, the definite process of neuroprotection in animal models of the
disease is controversial, given that some reports suggest non-CB receptor-dependent mecha‐
nisms. In this form, pharmacological usage of cannabinoids would provide the needed pieces
to elucidate the pathogenesis of ALS, as well as thoroughly justify its applications.
In contrast, though metabolic disorders such as OAs could get enormous benefit from a
renewed clinical outlook, data in regard to the link between the pathophysiology of the disease
and the potential uses of elements of the ECS are still incipient, and studies comprising both
variables are scarce. Oxidative stress and excitotoxicity are known to be implicated among
several processes stimulated during the development of OAs. Under this understanding, an
experimental approach determined the effects of WIN 55,212-2, a synthetic agonist of
cannabinoid receptors known for eliciting analgesic properties on several animal models. This
preclinical study reported that an experimental design administrating WIN 55,212-2 as
pretreatment was sufficient to induce protective effects on early markers of endogenous
metabolites that tend to be produced and accumulated in OAs; in addition, decrease in levels
of ROS was also noted [58]. Despite limited, such emerging data can substantiate further
research under the same paradigm, with the aims of assembling an alternative capable of
preventing the formation of ROS, as well as lipid peroxidation, systematic events found to be
exerted by toxic metabolites of OAs.
4. Concluding remarks
Neurological illnesses, such as the ones mentioned in this chapter, pose exceptional challeng‐
es for therapy and technology while conversely carry great predicaments for human quality
of life and morbidity (See Figure 1). Oxidative stress, inflammation, excitotoxicity, and
degeneration itself conform the basis of many diseases addressed in this revision; moreover,
such factors constitute harbingers of mortality. Thus, diverse treatment paths need to be
followed to advance towards fruitful options. In this form, the understanding of the physio‐
logical and functional consequences of the molecular changes comprised during health and
disease is crucial. In this journey, the involvement of the ECS and its many angles has arisen,
and the therapeutic approximations resulting from its employment have found a counter‐
part in many diseases that bear scenarios of great defies for both patients and clinicians, and
unfortunately, many roadblocks lie ahead. Ideally such obstacles would be overcome through




the establishment of compatible tests and measures for accurate and timely diagnosis, the
addressing of the actual mechanisms of its pathogenesis, the proposal, and assessment of
future protective therapies, and the development of prevention strategies for individuals at
risk if applicable. Novel developments have driven scientific excitement to a new high; in this
form, the pace of experimental research shows that neuroscience is headed towards the
integration of the current clinical needs, with novel discoveries and technology. For these
reasons, numerous researches cast a spotlight into the ECS, given the intimate relationship of
these and pathological processes; in addition, its lipophilic qualities along with the remarka‐
ble low toxicity of its derivatives enable exogenous and synthetic cannabinoids as suitable
strategies, hence avoiding common inconveniences and side effects commonly presented with
traditional therapies. Besides, the challenges facing a future implementation to thwart
neurodegenerative diseases are vast, and needless to say, misleading information in regard to
safety and efficacy of cannabinoid-based therapies overwhelms general public, and appropri‐
ate studies must allow the substantiation of the viability of the endocannabinoid modulation
as a strategy against neurodegeneration, and more importantly, would determine if the overall
benefits outweigh all realistic disadvantages.
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Figure 1. Schematic representation of the neurological diseases acquiring therapeutic options based on cannabinoid
chemistry.
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